BACKGROUND: Aortic stiffness and left ventricular hypertrophy (LVH) are predictors of mortality in hemodialysis (HD) patients. Attenuation of arterial stiffness and regression of LVH had a favorable effect on survival in these patients, but this favorable effect was observed in less than 50% of patients, the rest being resistant to therapeutical interventions. The aim of this study was to analyze the factors associated with this resistance to treatment. METHODS: 138 patients on HD were studied during a follow-up survey. From entry until the end of follow up, the changes of aortic pulse wave velocity (PWV) and of LV mass were measured in response to treatment with antihypertensive drugs and erythropoietin, together with measurements of blood chemistry, including high-sensitive C-reactive protein (CRP). Patients with decreased aortic PWV were considered to be responders (N = 68), the others to be nonresponders (N = 70). RESULTS: Nonresponders were older (P < 0.05) and had persistently higher systolic blood pressure (BP) and pulse pressure. Responders were treated more frequently with an ACE inhibitor (P < 0.001), and had lower serum CRP (P < 0.01). The baseline PWV, as well as the changes of PWV and LV mass during the follow-up were significantly and independently correlated with serum CRP level (P < 0.001). According to logistic regression after adjustment for age, gender, diabetes, history of CVD, and the nonspecific cardiovascular risk factors, the improvement of aortic stiffness and LV hypertrophy was positively associated with prescription of ACE inhibitor (P < 0.0001), and negatively with the serum CRP level (P < 0.01). CONCLUSION: These results indicate that in HD patients, the presence of low-grade inflammation decreases the efficiency of cardiovascular therapeutic interventions and participates in the persistence of cardiovascular hemodynamic overload.
BACKGROUND: Aortic stiffness and left ventricular hypertrophy (LVH) are predictors of mortality in hemodialysis (HD) patients. Attenuation of arterial stiffness and regression of LVH had a favorable effect on survival in these patients, but this favorable effect was observed in less than 50% of patients, the rest being resistant to therapeutical interventions. The aim of this study was to analyze the factors associated with this resistance to treatment. METHODS: 138 patients on HD were studied during a follow-up survey. From entry until the end of follow up, the changes of aortic pulse wave velocity (PWV) and of LV mass were measured in response to treatment with antihypertensive drugs and erythropoietin, together with measurements of blood chemistry, including high-sensitive C-reactive protein (CRP). Patients with decreased aortic PWV were considered to be responders (N = 68), the others to be nonresponders (N = 70). RESULTS: Nonresponders were older (P < 0.05) and had persistently higher systolic blood pressure (BP) and pulse pressure. Responders were treated more frequently with an ACE inhibitor (P < 0.001), and had lower serum CRP (P < 0.01). The baseline PWV, as well as the changes of PWV and LV mass during the follow-up were significantly and independently correlated with serum CRP level (P < 0.001). According to logistic regression after adjustment for age, gender, diabetes, history of CVD, and the nonspecific cardiovascular risk factors, the improvement of aortic stiffness and LV hypertrophy was positively associated with prescription of ACE inhibitor (P < 0.0001), and negatively with the serum CRP level (P < 0.01). CONCLUSION: These results indicate that in HDpatients, the presence of low-grade inflammation decreases the efficiency of cardiovascular therapeutic interventions and participates in the persistence of cardiovascular hemodynamic overload.
Authors: Victor H Urbieta-Caceres; Xiang-Yang Zhu; Kyra L Jordan; Hui Tang; Kyle Textor; Amir Lerman; Lilach O Lerman Journal: Atherosclerosis Date: 2011-10-12 Impact factor: 5.162
Authors: Gabriel Contreras; Bo Hu; Brad C Astor; Tom Greene; Thomas Erlinger; John W Kusek; Michael Lipkowitz; Julia A Lewis; Otelio S Randall; Lee Hebert; Jackson T Wright; Cynthia A Kendrick; Jennifer Gassman; George Bakris; Joel D Kopple; Lawrence J Appel Journal: J Am Soc Nephrol Date: 2010-09-23 Impact factor: 10.121
Authors: Eliot Peyster; Jing Chen; Harold I Feldman; Alan S Go; Jayanta Gupta; Nandita Mitra; Qiang Pan; Anna Porter; Mahboob Rahman; Dominic Raj; Muredach Reilly; Maria R Wing; Wei Yang; Raymond R Townsend Journal: Am J Hypertens Date: 2017-04-01 Impact factor: 2.689
Authors: Raymond R Townsend; Neil J Wimmer; Julio A Chirinos; Afshin Parsa; Matthew Weir; Kalyani Perumal; James P Lash; Jing Chen; Susan P Steigerwalt; John Flack; Alan S Go; Mohammed Rafey; Mahboob Rahman; Angela Sheridan; Crystal A Gadegbeku; Nancy A Robinson; Marshall Joffe Journal: Am J Hypertens Date: 2009-12-17 Impact factor: 2.689
Authors: Renate Schnabel; Martin G Larson; Josée Dupuis; Kathryn L Lunetta; Izabella Lipinska; James B Meigs; Xiaoyan Yin; Jian Rong; Joseph A Vita; Christopher Newton-Cheh; Daniel Levy; John F Keaney; Ramachandran S Vasan; Gary F Mitchell; Emelia J Benjamin Journal: Hypertension Date: 2008-04-21 Impact factor: 10.190
Authors: Xiang-Yang Zhu; Alejandro R Chade; James D Krier; Elena Daghini; Ronit Lavi; Angelo Guglielmotti; Amir Lerman; Lilach O Lerman Journal: J Hypertens Date: 2009-10 Impact factor: 4.844